Sngine
Résultats de Recherche
Voir tous les résulats
  • Nous rejoindre
    Se connecter
    S’enregistrer
    Rechercher
    Sélecteur de thème
    Mode nuit

Rechercher

Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis

  • Fil d’actualités
  • EXPLORER
  • Pages
  • Groupes
  • Evènements
  • Reels
  • Blogs
  • Offres
  • Emplois
  • Articles
  • Blogs
  • Utilisateurs
  • Pages
  • Groupes
  • Evènements
  • Pratiksha Dhote Ajouter une nouvelle offre d'emploi Health
    2026-01-22 11:15:00 -
    Biosimilars and the Shift in Market Accessibility
    The high cost of biologic medicine has long been a barrier to patient access. However, as the patents for the first generation of blockbuster Fc fusion proteins begin to expire, the doors are opening for biosimilars. A biosimilar is a biological product that is highly similar to an already approved "reference" drug. The rise of these competitors is fostering a more competitive environment,...
    0 Commentaires 0 Parts 209 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • Anuj Mrfr Ajouter une nouvelle offre d'emploi Health
    2026-03-30 13:27:07 -
    Biosimilars Market: How Are Insulin Biosimilars Transforming Diabetes Treatment Access?
    Insulin biosimilars — providing lower-cost alternatives to branded insulin analogues for millions of insulin-dependent diabetic patients — represent a critical healthcare access biosimilar application where the human and economic stakes of affordability are most directly apparent, with the Biosimilars Market reflecting insulin biosimilars' public health significance. Insulin...
    0 Commentaires 0 Parts 7 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • Pratik Patil Ajouter une nouvelle offre d'emploi Health
    2026-02-25 06:22:20 -
    Omalizumab Monoclonal Antibody Biosimilars Market Trends and Competitive Landscape
    The transition of omalizumab from patented biologic to biosimilar alternatives is one of the most important stories in modern therapeutic manufacturing. The Omalizumab Monoclonal Antibody Biosimilars Market captures this evolution, showcasing how biosimilar competition can reshape patient care and industry economics. As original patents expire, more companies are entering the development...
    0 Commentaires 0 Parts 124 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • Rutuja Bhosale Ajouter une nouvelle offre d'emploi Autre
    2025-12-08 07:47:10 -
    Ultomiris Drug Market Will Biosimilars Disrupt the Ultomiris Drug Market Before 2035?
    Ultomiris Drug Market Overview 2025–2033: Size, Growth Drivers, Key Companies, Segments, and Future Outlook The Ultomiris drug market is experiencing one of the fastest growth trajectories in the rare disease and biologics sector. According to the latest industry analysis, the global Ultomiris drug market size is expected to expand from USD 5.2 billion in...
    0 Commentaires 0 Parts 290 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • Pratiksha Dhote Ajouter une nouvelle offre d'emploi Health
    2025-12-13 11:05:58 -
    Analytical Biosimilar Market Data: Ensuring Equivalence and Optimizing Use Cases for Delivery Devices Names in Chronic Conditions
    The foundation of the Biosimilars Market Data is the comprehensive analytical comparison required to demonstrate 'fingerprint-like' similarity between the biosimilar and the reference biologic. This meticulous data, generated using advanced specific technologies like mass spectrometry and various bioassays, is the core evidence presented to regulatory bodies to secure approval. The use cases...
    0 Commentaires 0 Parts 295 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • Shubhangi Fusam Ajouter une nouvelle offre d'emploi Health
    2025-11-19 12:17:45 -
    Asia-Pacific’s Next Frontier: Increasing Patient Population and Biotechnology Advancements Accelerate Growth in the Fastest-Growing Region.
    A critical factor enabling the success of the biosimilars market is the development of robust, globally harmonized regulatory frameworks. Agencies like the U.S. FDA and the European Medicines Agency (EMA) have spent years establishing rigorous scientific criteria to demonstrate 'biosimilarity'—proving that the biosimilar is highly similar to the reference product with no clinically...
    0 Commentaires 0 Parts 448 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
© 2026 Sngine French
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Environ Conditions générale de vente Confidentialité Contactez nous Annuaire